The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
Lecanemab-irmb's subcutaneous administration maintains clinical benefits comparable to intravenous dosing in patients with early Alzheimer disease. The safety profile of subcutaneous dosing is ...
Barriers and facilitators to seeking care for the initial diagnosis of melanoma in an urban safety-net hospital. Time Impact on time related to treatment, travel, personal, work or social activities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results